Donderdag <strong>22</strong> <strong>maart</strong> <strong>2012</strong> 10.54 Bone Morphogentic Protein 4 signaling alters microRNA-145 expression in the esophagus J.W.P.M. van Baal 1 , M. Fassan 2 , R.F. Souza 3 , S.J. Spechler 3 , M. Rugge 2 , P.D. Siersema 1 , 1Dept. of <strong>Gastro</strong>enterology and Hepatology, University Medical Center Utrecht, The Netherlands, 2 Dept. of Medical Diagnostic Sciences and Special Therapies, Surgical Pathology and Cytopathology Unit, University of Padova, Padova, Italy, 3 Dept. of Medicine, UT Southwestern Medical Center, Dallas, TX, USA 11.06 Enhanced tumor growth after portal vein embolization in a rabbit VX2 tumor model L.T. Hoekstra 1 , K.P. van Lienden 2 , J. Verheij 3 , M. Heger 1 , T.M. van Gulik 1 , 1 Dept. of Surgery, Academic Medical Center, Amsterdam, 2 Dept. of Radiology, Academic Medical Center, Amsterdam, 3 Dept. of Pathology, Academic Medical Center, Amsterdam, The Netherlands 11.18 Invited Speaker Bile duct development in relation to cholangiopathies Prof. F. Lemaigre, de Duve Institute, University Leuven, België 12.00 Lunch en postersessie Postersessie DEGH Meierij Foyer 12.00 De postersessie van de DEGH vindt plaats tussen 12.00 en 13.30 uur met vanaf 12.45 de mogelijkheid om u aan te sluiten bij een begeleide sessie langs de posters. Vier tot vijf posters per categorie, 7 minuten per poster, zie pagina 41 e.v. De posters moeten tot aan het eind van het programma op vrijdagmiddag blijven hangen. Over de posterprijzen wordt vrijdag tijdens de lunch beslist. 13.30 Vervolg DEGH-programma. <strong>Nederlandse</strong> <strong>Vereniging</strong> <strong>voor</strong> <strong>Gastro</strong>enterologie Parkzaal Voorzitters: A.A. van Bodegraven en P.C.F. Stokkers Voordrachten in het Nederlands, spreektijd 7 minuten, discussietijd 3 minuten 10.00 Clarifying the role of the HLA in Ulcerative Colitis by extensive finemapping of a Dutch cohort R.M. Nijmeijer 1,2* , E.A.M. Festen 2,3* , D.J. de Jong 4,5 , H.W. Verspaget 6 , C.Y. Ponsioen 5 , R.K. Weersma 3 , 1 Dept. of Surgery, University Medical Center Utrecht, Utrecht, 2 Dept. of Genetics, University Medical Center Groningen and University of Groningen, Groningen, 3Dept. of <strong>Gastro</strong>enterology and Hepatology, University Medical Center Groningen, Groningen, 4 Dept. of <strong>Gastro</strong>enterology and Hepatology, Radboud University Nijmegen Medical Centre, Nijmegen, 5 Dept. of <strong>Gastro</strong>enterology and Hepatology, Academic Medical Center, Amsterdam, 6 Dept. of <strong>Gastro</strong>enterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands * Equal contribution 10
Donderdag <strong>22</strong> <strong>maart</strong> <strong>2012</strong> 10.10 Once-daily versus twice-daily mesalazine (Pentasa ® ) for active ulcerative colitis. Efficacy results from MOTUS, a multicentre, controlled, randomised, investigatorblinded study J.Ph. Kuyvenhoven 1 , B. Flourié 2 , H. Hagège 3 , G. Tucat 4 , Masclee 5 , M. Pierik 5 , O. Dewit 6 , P. Broberg 7 , W.K.H. Man A Hing 8 , 1 Kennemer Gasthuis, Haarlem, The Netherlands, 2 Lyon Sud Hospital, France, 3 ANGH (Association Nationale des <strong>Gastro</strong>entérologues des Hôpitaux), France, 4 CREGG (Club de Réflexion des Cabinets et Groupes d’Hépato-<strong>Gastro</strong>entérologie), France, 5 Maastricht University Medical Center, The Netherlands, 6 UCL Saint Luc, Brussels, Belgium, 7 Ferring Pharmaceuticals, Switzerland, 8 Ferring BV, The Netherlands 10.20 Is there a difference in quality of life or costs between ulcerative colitis patients with a pouch or an ileostomy? M.E. van der Valk 1 , M.J.J. Mangen 2 , G. Dijkstra 3 , A.A. van Bodegraven 4 , H.H. Fidder 1 , D.J. de Jong 5 , M. Pierik 6 , C.J. van der Woude 7 , M.J.L. Romberg-Camps 8 , C.H.M. Clemens 9 , J.M. Jansen 10 , P.C. van de Meeberg 11 , N. Mahmmod 12 , C.Y. Ponsioen 13 , C. Rogge-Wolf 14 , J. Reinoud Vermeijden 15 , P.D. Siersema 1 , M.G.H. van Oijen 1,2 , B. Oldenburg 1 on behalf of the COIN study group and Dutch Initiative on Crohn and Colitis, 1 Dept. of <strong>Gastro</strong>enterology and Hepatology, University Medical Center Utrecht, Utrecht, 2 Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, 3 Dept. of <strong>Gastro</strong>enterology and Hepatology, University Medical Center Groningen, Groningen, 4 Dept. of <strong>Gastro</strong>enterology and Hepatology, VU University Medical Center, Amsterdam, 5 Dept. of <strong>Gastro</strong>enterology and Hepatology, Radboud University Nijmegen Medical Center, Nijmegen, 6 Dept. of <strong>Gastro</strong>enterology and Hepatology, Maastricht University Medical Center, Maastricht, 7Dept. of <strong>Gastro</strong>enterology and Hepatology, Erasmus University Medical Center, Rotterdam, 8Dept. of <strong>Gastro</strong>enterology and Hepatology, Orbis Medical Center, Sittard, 9 Dept. of <strong>Gastro</strong>enterology and Hepatology, Diaconessenhuis, Leiden, 10 Dept. of <strong>Gastro</strong>enterology and Hepatology, Onze Lieve Vrouwe Gasthuis, Amsterdam, 11 Dept. of <strong>Gastro</strong>enterology and Hepatology, Slingeland Hospital, Doetinchem, 12 Dept. of <strong>Gastro</strong>enterology and Hepatology, Antonius Hospital, Nieuwegein, 13 Dept. of <strong>Gastro</strong>enterology and Hepatology, Academic Medical Center Amsterdam, 14 Dept. of <strong>Gastro</strong>enterology and Hepatology, Reinier de Graaf Groep, Delft, 15 Dept. of <strong>Gastro</strong>enterology and Hepatology, Meander Medical Center, Amersfoort, The Netherlands 10.30 Ulcerative colitis patients with an inflammatory response upon mesalazine cannot be desensitized. A single-blind randomized study D.J. Buurman 1 , J.G.R. De Monchy 2 , R.C.A. Schellekens 3 , L.A. van der Waaij 4 , J.H. Kleibeuker 1 , G. Dijkstra 1 , 1 Universitair Medisch Centrum Groningen, afdeling Maag-darm-leverziekten, 2Universitair Medisch Centrum Groningen, afdeling Immunologie en Allergologie, 3 Universitair Medisch Centrum Groningen, afdeling klinische pharmacologie, 4Martiniziekenhuis Groningen, afdeling Maag-, darm-, leverziekten, The Netherlands 10.40 Fatigue in IBD patients is associated with differencesin immune parameters C. de Haar 1 , L. Vogelaar 1 , B.Aerts 1 , M.P. Peppelenbosch 1 , E.J. Kuipers 1 , C. Janneke van der Woude 1 , 1 Dept. of <strong>Gastro</strong>enterology & Hepatology, Erasmus MC, Rotterdam, The Netherlands 10.50 Anti TNF-α therapy is a major cost driver in inflammatory bowel disease. Results from the COIN study M. E. van der Valk 1 , M.J.J. Mangen 2 , G. Dijkstra 3 , A.A. van Bodegraven 4 , H.H. Fidder 1 , D.J. de Jong 5 , M. Pierik 6 , C.J. van der Woude 7 , M.J.L. Romberg-Camps 8 , C.H.M. Clemens 9 , J.M. Jansen 10 , P.C. van de Meeberg 11 , N. Mahmmod 12 , C.Y. Ponsioen 13 , C. Rogge-Wolf 14 , J. Reinoud Vermeijden 15 , P.D. Siersema 1 , M.G.H. van Oijen 1,2 , B. Oldenburg 1 on behalf of the 11